Abstract:Background: Lysophosphatidic acid (LPA) is an important extracellular signal transmitter and intracellular second messenger in body fluids. It can be detected in the ascitic fluid of patients with ovarian cancer. Increasing evidence shows that LPA can stimulate cancer cell proliferation and promote tumor invasion and metastasis. Our study aimed to evaluate the diagnostic value of LPA in differentiating between malignant pleural effusions (MPEs) and benign pleural effusions (BPEs) and to evaluate the association between the level of LPA in MPE and the prognosis of lung cancer patients.Patients and methods: The level of LPA in the pleural effusions (PEs) of 123 patients (94 MPE, 29 BPE) with lung cancer was evaluated using an enzyme-linked immunosorbent assay. The performance of LPA was analyzed by standard Receiver operator characteristic curve (ROC) analysis methods, using the area under the curve (AUC) as a measure of accuracy. Overall survival (OS) curves and progression-free survival (PFS) curves were based on the Kaplan-Meier method, and the survival differences between subgroups were analyzed using the log-rank or Breslow test (SPSS software). A multivariate Cox proportional hazards model was used to assess whether LPA independently predicted lung cancer survival.Results: The levels of LPA differed significantly between MPE (22.08 +/- 8.72 mu g/L) and BPE (14.61 +/- 5.12 mu g/L) (P<0.05). Using a cutoff point of 18.93 mu g/L, LPA had a sensitivity of 60% and a specificity of 83% to distinguish MPEs from BPEs with an AUC of 0.769 +/- 0.045 (SE) (P=0.000) (95% CI, 0.68-0.857). In the three pathological types of lung cancer patients with MPE, there were no significant associations between LPA levels and the length of PFS and OS (P=0.58 and 0.186, respectively). Interestingly, in the patients with MPE caused by lung adenocarcinoma there were significant associations between the LPA levels and the PFS and OS (P=0.018 and 0.026, respectively). Multivariate analysis showed that the LPA level was an independent prognostic factor for PFS in lung adenocarcinoma.Conclusions: Our results indicate that LPA can be used as a new biomarker for the diagnosis of MPE caused by lung cancer and that higher levels of LPA are related to shorter PFS in adenocarcinoma of the lung.

Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 with Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer

Study of Telomerase Activity in Pleural Lavage Fluid Specimens in Patients with Non-Small-cell Lung Cancer and Its Clinical Significance

Diagnostic and Prognostic Significance of Receptor‐binding Cancer Antigen Expressed on SiSo Cells in Lung‐cancer‐associated Pleural Effusion

Vascular Endothelial Growth Factor and Soluble Intercellular Adhesion Molecule-1 in Lung Adenocarcinoma with Malignant Pleural Effusion: Correlations with Patient Survival and Pleural Effusion Control

The expression levels of VEGF and ICAM-1 in pleural effusion

Prognostic Value of Secreted Phosphoprotein-1 in Pleural Effusion Associated with Non-Small Cell Lung Cancer.

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Diagnostic Value of Pleural Effusion for the Detection of EGFR in NSCLC: a Meta-Analysis

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

SPP1 expressed in malignant pleural effusion in patients with advanced lung cancer and its value for diagnosis

High Expression of E-cadherin in Pleural Effusion Cells Predicts Better Prognosis in Lung Adenocarcinoma Patients.

Diagnostic and Prognostic Significance of Lysophosphatidic Acid in Malignant Pleural Effusions.

Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion

Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis

Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer

Synificance of Vascular Endothelial Growth Factor Level in Patients with Malignant Pleural Effusion

Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.

Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis

Diagnostic Performance of CTLA-4, Carcinoembryonic Antigen and CYFRA 21-1 for Malignant Pleural Effusion

Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study

Carcinoembryonic Antigen in Pleural Effusion of Patients with Lung Adenocarcinoma: a Predictive Marker for EGFR Mutation